As efforts are being made to develop HLA-agnostic CAR T cells, specific to only the peptide and not the MHC, we believe these tools will be useful in identifying broader segments of the cancer population likely to benefit from these immunotherapies. This evidence concerns the gene HLA-C and cancer.